Menu Search
Equities

OPKO Health Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
XCY:DUS

OPKO Health Inc

Actions
  • Price (EUR)1.04
  • Today's Change-0.01 / -0.95%
  • Shares traded101.00
  • 1 Year change-32.77%
  • Beta1.4844
Data delayed at least 15 minutes, as of Feb 06 2026 18:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

  • Revenue in USD (TTM)642.07m
  • Net income in USD-180.40m
  • Incorporated1991
  • Employees3.00k
  • Location
    OPKO Health Inc4400 Biscayne Blvd.MIAMI 33137United StatesUSA
  • Phone+1 (305) 575-4181
  • Websitehttps://www.opko.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.